Principia Biopharma Inc. (PRNB)
Stock Price:
$56.82 USD
0.44 (0.77%)
Updated Jul 9, 2020 1:21 PM EDT - Market open
Key Info
| Market Cap |
1.88B |
| Revenue (ttm) |
30.00M |
| Net Income (ttm) |
-72.60M |
| Shares Out |
33.04M |
| EPS (ttm) |
-2.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$56.82 |
| Previous Close |
$56.38 |
| Change ($) |
0.44 |
| Change (%) |
0.77% |
| Day's Open |
56.30 |
| Day's Range |
53.36 - 57.50 |
| Day's Volume |
109,769 |
| 52-Week Range |
25.35 - 75.65 |
More Stats
| Market Cap |
1.88B |
| Enterprise Value |
1.58B |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.04M |
| Float |
22.84M |
| EPS (basic) |
-2.5 |
| EPS (diluted) |
-2.59 |
| FCF / Share |
-1.65 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.31M |
| Short Ratio |
7.15 |
| Short % of Float |
9.54% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
62.57 |
| PB Ratio |
5.58 |
| Revenue |
30.00M |
| Operating Income |
-78.01M |
| Net Income |
-72.60M |
| Free Cash Flow |
-54.59M |
| Net Cash |
296.90M |
| Net Cash / Share |
8.99 |
| Gross Margin |
117.20% |
| Operating Margin |
-260.02% |
| Profit Margin |
-242.00% |
| FCF Margin |
-181.95% |
| ROA |
-18.01% |
| ROE |
-29.61% |
| ROIC |
-32.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$81.88*
(44.12% upside)
Low
72.0
Current: 56.82
High
100.0
Target: 81.88
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 35.16 | 69.14 | 5.25 | - |
| Revenue Growth | -49.14% | 1217.65% | - | - |
| Gross Profit | 35.16 | 69.14 | 5.25 | - |
| Operating Income | -58.77 | 17.14 | -26.59 | -27.05 |
| Net Income | -53.79 | 4.92 | -28.70 | -30.64 |
| Shares Outstanding | 25.78 | 7.62 | 0.57 | 0.51 |
| Earnings Per Share | -2.09 | 0.57 | -50.37 | -59.89 |
| Operating Cash Flow | -42.55 | -21.17 | 26.85 | -24.84 |
| Capital Expenditures | -2.17 | -1.07 | -0.09 | -0.01 |
| Free Cash Flow | -44.72 | -22.24 | 26.76 | -24.86 |
| Cash & Equivalents | 316 | 177 | 41.15 | 5.97 |
| Total Debt | - | - | - | 14.45 |
| Net Cash / Debt | 316 | 177 | 41.15 | -8.49 |
| Assets | 383 | 196 | 43.50 | 7.56 |
| Liabilities | 23.76 | 25.66 | 58.43 | 19.28 |
| Book Value | 359 | 170 | -143 | -117 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Principia Biopharma Inc. |
| Country |
United States |
| Employees |
105 |
| CEO |
Martin Babler |
Stock Information
| Ticker Symbol |
PRNB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PRNB |
| IPO Date |
September 14, 2018 |
Description
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-medicated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.